Lacidipina Eg (Lacidipine)

Lacidipine belongs to the calcium channel blocker class and is employed in the management of elevated blood pressure.

• Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension.
• Isolated systolic hypertension: improves vascular tone and reduces systolic pressure in older adults.
• Secondary hypertension: assists in blood‑pressure control when hypertension is due to another underlying condition.

• Lacidipine selectively inhibits L‑type calcium channels on vascular smooth‑muscle cells, decreasing calcium influx. This reduction leads to relaxation of arterial smooth muscle, resulting in vasodilation and a subsequent fall in peripheral vascular resistance, which lowers systemic blood pressure.

Lacidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: warm sensation, often on the face.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness, especially after standing.
• Tachycardia: increased heart rate.
• Nausea or abdominal discomfort.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Angioedema: swelling of lips, tongue, or throat.
• Hepatic dysfunction: abnormal liver enzymes.
• Myocardial infarction: rare but possible cardiac event.
• Arrhythmias: irregular heart rhythms.
• Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy with Lacidipine, several safety considerations should be observed.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Cardiac evaluation: review history of heart failure or recent myocardial infarction.
• Concomitant antihypertensives: adjust doses to prevent additive effects.
• Hepatic impairment: use with caution and consider dose adjustment.
• Abrupt discontinuation: taper gradually to avoid rebound hypertension.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lacidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Lacidipine plasma levels.
• Other calcium‑channel blockers: additive vasodilatory effect leading to hypotension.
• Grapefruit juice: can raise drug concentration and risk of side effects.
• Concurrent antihypertensives (e.g., ACE inhibitors, beta‑blockers): may cause excessive blood‑pressure reduction.
• Digoxin: increased risk of cardiac toxicity.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.
• Diuretics: may enhance orthostatic hypotension.
• NSAIDs: can blunt antihypertensive response.
• Alcohol: may potentiate dizziness and hypotension.
• Lipid‑lowering agents (e.g., statins): monitor for altered metabolism.